TIPTOP: Evaluating the Effects of Community Delivery of Malaria Intermittent Preventive Treatment on Pregnant Women and Babies

Sponsor
Jhpiego (Other)
Overall Status
Completed
CT.gov ID
NCT03600844
Collaborator
Barcelona Institute for Global Health (Other)
10,602
12
2
43
883.5
20.6

Study Details

Study Description

Brief Summary

This study evaluates the effectiveness of community delivery of sulfadoxine-pyrimetamine (SP) for intermittent preventive treatment of malaria in pregnancy (IPTp) in increasing the coverage of IPTp among pregnant women in selected districts in Democratic Republic of Congo (DRC), Madagascar, Mozambique and Nigeria, compared to comparison districts where SP for IPTp is distributed as usual in facilities through routine antenatal care (ANC).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Community distribution of SP for IPTp
N/A

Detailed Description

The specific objectives of this study are to determine the change in the following indicators during the course of the TIPTOP project: 1) Proportion of women who have had a pregnancy that ended in the past 12 months and have received 1 or more, 2 or more and 3 or more doses of IPTp-SP; proportion of women with pregnancy in the past 12 months who attended ANC clinics at least once, and who attended at least four times; proportion of pregnant women attending the first ANC visit before or at week 14; proportion of women who have had a pregnancy that ended in the past 12 months who know about the IPTp service provided by CHWs; and acceptability of C-IPTp for community delivery of IPTp (note: results will be disaggregated by provider type, age, gravidity and distance from facility). To assess these changes, the study will implement structured household surveys targeting potential beneficiaries of the project (pregnant women) in the intervention and comparison areas, implemented at three time points: baseline, mid- and end-points. In each country an initial implementation area (Phase I) and two expansion areas (Phase II) have been selected for the project. This study will establish if community deliver of IPTp is effective and feasible and whether it influences antenatal care service coverage rates. It is expected that the study will provide information to scale up the approach the 4 study countries for the prevention of malaria in pregnancy. This information is also meant to inform global guidelines on community IPTp delivery and may also be used by other countries.

Study Design

Study Type:
Interventional
Actual Enrollment :
10602 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Districts in high malaria transmission zones were assigned to intervention and comparison areas.Districts in high malaria transmission zones were assigned to intervention and comparison areas.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Evaluation of Community Delivery of Malaria Intermittent Preventive Treatment in Pregnancy (C-IPTp) (TIPTOP Project)
Actual Study Start Date :
Apr 2, 2018
Actual Primary Completion Date :
Oct 31, 2021
Actual Study Completion Date :
Oct 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Phase 1 Intervention

Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.

Behavioral: Community distribution of SP for IPTp
SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
Other Names:
  • C-IPTp-SP
  • Active Comparator: Phase 1 Comparison/Phase 2 Intervention

    During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.

    Behavioral: Community distribution of SP for IPTp
    SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
    Other Names:
  • C-IPTp-SP
  • Outcome Measures

    Primary Outcome Measures

    1. IPTp3 Coverage [1 year]

      Proportion of women who had a pregnancy ending in the past 12 months and have received three or more doses of IPTp-SP

    Secondary Outcome Measures

    1. IPTp1 Coverage [1 year]

      Proportion of women who have had a pregnancy that ended in the past 12 months and have received one or more doses of IPTp-SP

    2. ANC 4 coverage [1 year]

      • Proportion of women who have had a pregnancy that ended in the past 12 months and have attended ANC clinics four times

    3. ANC 1 Coverage [1 year]

      Proportion of women who have had a pregnancy that ended in the past 12 months and have attended ANC clinics at least once

    4. Early ANC Coverage [1 year]

      Proportion of pregnant women attending the first ANC visit before or at week 14

    5. C-IPTp Knowledge [1 year]

      Proportion of women who have had a pregnancy that ended in the past 12 months who know about the IPTp service provided by CHWs

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 49 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Women who had a pregnancy that ended in the 12 months preceding the survey

    • Being resident in the study area during for at least 4 months before the end of the pregnancy

    • Willing to participate in the household survey (signing informed consent/assent, in line with country guidelines)

    Exclusion Criteria:
    • Anyone considered to be a minor in their country.

    • Not willing to provide informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kenge District, Community Setting Kenge Kwango Congo, The Democratic Republic of the
    2 Bulungu District, Community Setting Bulungu Kwilu Congo, The Democratic Republic of the
    3 Community Setting Kunda Maniema Congo, The Democratic Republic of the
    4 Mananjary District, Community Setting Mananjary Fianarantsoa Madagascar
    5 Community Setting Toliary 2 Fianarantsoa Madagascar
    6 Community Setting Vohipeno Vatovavy-Fitovinany Madagascar
    7 Meconta District, Community Setting Meconta Nampula Mozambique
    8 Community Setting Murrupula Nampula Mozambique
    9 Nhamatanda District, Community Setting Nhamatanda Sofala Mozambique
    10 Community Setting Ohaukwu District Ebonyi Nigeria
    11 Community Setting Bosso Niger Nigeria
    12 Community Setting Akure South Ondo Nigeria

    Sponsors and Collaborators

    • Jhpiego
    • Barcelona Institute for Global Health

    Investigators

    • Principal Investigator: Clara Menendez, MD, PhD, Barcelona Institute for Global Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jhpiego
    ClinicalTrials.gov Identifier:
    NCT03600844
    Other Study ID Numbers:
    • TIPTOP_HHS_2018
    • 2017-13-TIPTOP
    First Posted:
    Jul 26, 2018
    Last Update Posted:
    Mar 31, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2022